ADSK
65
-2
INTU
60
-3
V
64
-4
CTAS
56
-5
UHS
58
4
TJX
50
2
UNP
48
-2
STX
53
-4
MCD
63
-4
LMT
40
-5
DTE
56
-7
SHW
71
-2
NUE
50
3
TGT
50
2
PWR
60
-2
MNST
52
2
JNJ
51
-2
HPQ
62
2
PM
52
-4
VRSN
50
-5
ADSK
65
-2
INTU
60
-3
V
64
-4
CTAS
56
-5
UHS
58
4
TJX
50
2
UNP
48
-2
STX
53
-4
MCD
63
-4
LMT
40
-5
DTE
56
-7
SHW
71
-2
NUE
50
3
TGT
50
2
PWR
60
-2
MNST
52
2
JNJ
51
-2
HPQ
62
2
PM
52
-4
VRSN
50
-5
Financhill
Back

Halozyme Therapeutics Quote, Financials, Valuation and Earnings

"EarnPhone": The Investment Hidden in Plain Sight

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
60

HALO
Halozyme Therapeutics

Last Price:
59.47
Seasonality Move:
10.79%

7 Day Trial

ALL ACCESS PASS

$ 7

32,481% Growth? Meet Mode Mobile's "EarnPhone"

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Halozyme Therapeutics Price Quote

$59.47
-2.84 (-4.56%)
(Updated: September 19, 2024 at 6:55 PM ET)

Halozyme Therapeutics Key Stats

Buy
60
Halozyme Therapeutics (HALO) is a Buy
Day range:
$61.30 - $63.50
52-week range:
$32.83 - $65.53
Dividend yield:
0%
P/E ratio:
29.67
P/S ratio:
9.33
P/B ratio:
27.27%
Volume:
1.2M
Avg. volume:
1.3M
1-year change:
59.32%
Market cap:
$7.9B
Revenue:
$829.3M
EPS:
$2.58

How Much Does Halozyme Therapeutics Make?

Is Halozyme Therapeutics Growing As A Company?

  • What Is Halozyme Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.05%
  • What Is Halozyme Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0.29%

Halozyme Therapeutics Stock Price Performance

What Is Halozyme Therapeutics 52-Week High & Low?

Halozyme Therapeutics Price To Free Cash Flow

Is It Risky To Buy Halozyme Therapeutics?

Is Halozyme Therapeutics Cash Flow Positive?

  • What Is HALO Cash Flow From Operations?
    Cash flow from operations (TTM) is $420M
  • What Is Halozyme Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$236.8M
  • What Is Halozyme Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$216.5M

Halozyme Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    HALO return on invested capital is 19.96%
  • What Is Halozyme Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 18.24%
  • What Is HALO Return On Equity?
    ROE is a measure of profitability and is 177.29%

Halozyme Therapeutics Earnings Date & Stock Price

Halozyme Therapeutics Competitors

Halozyme Therapeutics Dividend Yield

Halozyme Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 28.57% 20.1%
Revenue: 4.67% 12.89%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 3
Sell Recommendations: 0
Price Target: 60.60
Downside from Last Price: -2.74%

Major Shareholders

  • How many HALO shares are owned by institutional investors?
    193.5M HALO shares are owned by institutional investors
  • How many HALO shares are owned by insiders?
    11.5M HALO shares are owned by insiders